The protocol is compatible with representative cell lines for each of the four major molecular subtypes of breast cancer (including luminal A (T47D), HER2-enriched (BT474 and SK-BR-3), and triple-negative (MDA-MB-231) cell lines) and allows the incorporation of CAFs directly isolated from individual patients. This evidence concerns the gene ERBB2 and breast carcinoma.